GKOS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Glaukos Corp (GKOS) is not a strong buy at the moment for a beginner investor with a long-term strategy. While the company shows strong revenue growth and positive long-term catalysts, the current market sentiment, technical indicators, and financial performance suggest a wait-and-see approach. The lack of significant trading signals and the recent price decline further support holding off on an immediate investment.
The MACD is below zero and negatively contracting, indicating bearish momentum. RSI is neutral at 57.605, showing no clear trend. Moving averages are converging, and the stock is trading near resistance (R1: 119.424) but has declined by 3.22% in the regular market. The stock shows a high probability of minor declines in the short term (-0.58% in the next week, -1.61% in the next month).
Strong revenue growth of 35.66% YoY in Q4
Analysts have raised price targets, with most maintaining Buy or Overweight ratings.
FDA approval for repeat dosing of iDose, providing long-term growth opportunities.
Hedge funds are significantly increasing their positions in the stock.
Insiders are selling heavily, with a 1898.23% increase in selling activity over the last month.
The company reported a Q4 loss of $0.28 per share, missing expectations.
Short-term technical indicators suggest bearish momentum.
The stock price declined 3.22% in the regular market and shows a probability of further short-term declines.
In Q4 2025, revenue increased by 35.66% YoY to $143.1 million, and gross margin improved to 77.8%. However, net income remains negative at -$133.7 million, though it improved by 298.03% YoY. EPS also remains negative at -2.32, up 286.67% YoY. While the company shows strong revenue growth, profitability remains a concern.
Analysts are bullish on Glaukos, with multiple firms raising price targets (ranging from $127 to $160) and maintaining Buy or Overweight ratings. Analysts highlight the long-term growth potential of iDose and Epioxa, with significant revenue acceleration expected in 2027 and beyond.
